PMID: 7036780Jan 1, 1981Paper

Marrow transplantation in the treatment of acute childhood leukemia. Historical development and current approaches

The American Journal of Pediatric Hematology/oncology
F L Johnson

Abstract

The history of the development of marrow transplantation as a therapy for acute leukemia in childhood is reviewed together with the lessons learned from the first 110 patients transplanted for leukemia at the Fred Hutchinson Cancer Research Center and the Children's Orthopedic Hospital and Medical Center. This has led to the current approach which is to transplant patients earlier in remission but when their prognosis is poor. Recent results for marrow transplants in acute lymphoblastic and acute nonlymphocytic leukemias performed during remission are discussed.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.